88 related articles for article (PubMed ID: 26267334)
1. Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with kras(v12) Cells.
Belloni E; Martin Padura I; Gerbino E; Orecchioni S; Fusar Imperatore F; Marighetti P; Bertalot G; Giuseppe Pelicci P; Bertolini F
Sci Rep; 2015 Aug; 5():13047. PubMed ID: 26267334
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
[TBL] [Abstract][Full Text] [Related]
3. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
Cho HC; Lai CY; Shao LE; Yu J
Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
Green S; Trejo CL; McMahon M
Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
[TBL] [Abstract][Full Text] [Related]
5. Rare codons capacitate Kras-driven de novo tumorigenesis.
Pershing NL; Lampson BL; Belsky JA; Kaltenbrun E; MacAlpine DM; Counter CM
J Clin Invest; 2015 Jan; 125(1):222-33. PubMed ID: 25437878
[TBL] [Abstract][Full Text] [Related]
6. Inducible Intestine-Specific Expression of kras
Lu JW; Raghuram D; Fong PA; Gong Z
Neoplasia; 2018 Dec; 20(12):1187-1197. PubMed ID: 30390498
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis.
Satoh H; Moriguchi T; Takai J; Ebina M; Yamamoto M
Cancer Res; 2013 Jul; 73(13):4158-68. PubMed ID: 23610445
[TBL] [Abstract][Full Text] [Related]
8. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
9. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutation-positive bronchial surface epithelium (BSE)-type lung adenocarcinoma with strong expression of TTF-1: a case providing a further insight as for the role of TTF-1 in the oncogenesis.
Takanashi Y; Tajima S; Hayakawa T; Neyatani H; Funai K
Int J Clin Exp Pathol; 2015; 8(11):15338-43. PubMed ID: 26823891
[TBL] [Abstract][Full Text] [Related]
11. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
12. Genetic Evidence for XPC-KRAS Interactions During Lung Cancer Development.
Zhang X; He N; Gu D; Wickliffe J; Salazar J; Boldogh I; Xie J
J Genet Genomics; 2015 Oct; 42(10):589-596. PubMed ID: 26554912
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin drives KRAS-mutant lung adenocarcinoma.
Giopanou I; Kanellakis NI; Giannou AD; Lilis I; Marazioti A; Spella M; Papaleonidopoulos V; Simoes DCM; Zazara DE; Agalioti T; Moschos C; Magkouta S; Kalomenidis I; Panoutsakopoulou V; Lamort AS; Stathopoulos GT; Psallidas I
Carcinogenesis; 2020 Aug; 41(8):1134-1144. PubMed ID: 31740923
[TBL] [Abstract][Full Text] [Related]
14. Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Liu W; Yin Y; Wang J; Shi B; Zhang L; Qian D; Li C; Zhang H; Wang S; Zhu J; Gao L; Zhang Q; Jia B; Hao L; Wang C; Zhang B
Oncotarget; 2017 Jan; 8(1):179-190. PubMed ID: 27329725
[TBL] [Abstract][Full Text] [Related]
15. In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.
Ambrogio C; Barbacid M; Santamaría D
Oncogene; 2017 Apr; 36(16):2309-2318. PubMed ID: 27775074
[TBL] [Abstract][Full Text] [Related]
16. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
17. Decreased tumorigenesis in mice with a Kras point mutation at C118.
Huang L; Carney J; Cardona DM; Counter CM
Nat Commun; 2014 Nov; 5():5410. PubMed ID: 25394415
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation.
Banda M; McKim KL; Haber LT; MacGregor JA; Gollapudi BB; Parsons BL
Mutat Res Genet Toxicol Environ Mutagen; 2015 Aug; 789-790():53-60. PubMed ID: 26232258
[TBL] [Abstract][Full Text] [Related]
19. Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.
Yeddula N; Xia Y; Ke E; Beumer J; Verma IM
Proc Natl Acad Sci U S A; 2015 Nov; 112(47):E6476-85. PubMed ID: 26542681
[TBL] [Abstract][Full Text] [Related]
20. Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers.
Muzumdar MD; Dorans KJ; Chung KM; Robbins R; Tammela T; Gocheva V; Li CM; Jacks T
Nat Commun; 2016 Sep; 7():12685. PubMed ID: 27585860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
